Trial Profile
Individual Patient Expanded Access-Glembatumumab Vedotin
Status:
Discontinued
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 28 May 2018
Price :
$35
*
At a glance
- Drugs Glembatumumab vedotin (Primary)
- Indications Advanced breast cancer; Triple negative breast cancer
- Focus Expanded access; Therapeutic Use
- Sponsors Celldex Therapeutics Inc
- 16 Apr 2018 According to a Celldex Therapeutics media release, status changed from not yet recruiting to discontinued, because based on the data from METRIC study, company has decided to discontinue the glembatumumab vedotin program across all indications.
- 03 Mar 2017 New trial record